
## Ewa Wolinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2199248/publications.pdf Version: 2024-02-01



FWA MOLINSKA

#	Article	IF	CITATIONS
1	Epigenetic Changes in Gestational Diabetes Mellitus. International Journal of Molecular Sciences, 2021, 22, 7649.	4.1	20
2	Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers, 2021, 13, 4237.	3.7	10
3	An association of circulating Tregs and Th17 cells producing IL-21 and IL-22 with the ROMA in ovarian cancer patients. Cytokine, 2020, 134, 155194.	3.2	2
4	An association of iNKT+/CD3+/CD161+ lymphocytes in ovarian cancer tissue with CA125 serum concentration. Immunobiology, 2020, 225, 152010.	1.9	3
5	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 2019, 10, 3000.	12.8	194
6	Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma. European Journal of Histochemistry, 2019, 63, .	1.5	6
7	Immunohistochemical differentiation between muscularis mucosae and muscularis propria for improving the staging of bladder cancer in patients undergoing transurethral resection of bladder tumours. Polish Journal of Pathology, 2017, 68, 218-224.	0.3	3
8	Adrenal cyst with both Müllerian and mesothelial differentiation- a clinicopathological and immunohistochemical study with implications for histogenesis. Histology and Histopathology, 2017, 32, 1141-1149.	0.7	5
9	IL-6 and IL-8 enhance factor H binding to the cell membranes. Molecular Medicine Reports, 2016, 13, 3886-3894.	2.4	2
10	Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells. Oncology Letters, 2016, 12, 1507-1512.	1.8	5
11	Angiogenesis in CD5-positive Diffuse Large B Cell Lymphoma: A Morphometric Analysis. Advances in Clinical and Experimental Medicine, 2016, 25, 1149-1155.	1.4	5
12	The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin. Central-European Journal of Immunology, 2015, 3, 349-353.	1.2	5